Pulse Biosciences Files 510(k) Submission with U.S. FDA for

Pulse Biosciences, Inc. , a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, today...

Related Keywords

United States , Bioscience Cell , Kevin Danahy , Pulse Biosciences Inc , Exchange Commission , Drug Administration , Nasdaq , Company Cell , Pulse Biosciences , Pulsed Field Ablation , Chief Science Officer , Cardiac Surgery , Gan Dunnington , Chief Medical Officer , Chief Executive Officer , Nano Pulse Stimulation , Pulse Bioscience , Markets ,